Pfizer-Investor-Overview-at-2026-JPM-vFINAL2.pdf

《Pfizer-Investor-Overview-at-2026-JPM-vFINAL2.pdf》由会员分享，可在线阅读，更多相关《Pfizer-Investor-Overview-at-2026-JPM-vFINAL2.pdf（8页珍藏版）》请在三个皮匠报告上搜索。

1、1Pfizer Investor OverviewAt 2026 J.P.Morgan Healthcare ConferenceJanuary 20262Forward-Looking Statements and Non-GAAP Financial InformationOur discussions during this presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual

2、results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated operating and financial performance,including financial guidance and projections;reorganizations;changes to Pfizers R&D and commercial organi

3、zations;business plans,strategy,goals and prospects;expectations for our product pipeline(including products from completed or anticipated acquisitions),in-line products and product candidates,including anticipated regulatory submissions,data read-outs,study starts,approvals,launches,discontinuation

4、s,clinical trial results and other developing data,revenue contribution and projections,pricing and reimbursement,market dynamics,including demand,market size and utilization rates and growth,performance,timing of exclusivity and potential benefits;the impact and potential impact of tariffs and pric

5、ing dynamics;strategic reviews;leverage and capital allocation objectives;an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits);a manufacturing optimization program to reduce our cost of goods sold(including anticipated costs,savings and potential be

6、nefits);dividends and share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities,including our acquisition of Seagen,our acquisition of Metsera and our licensing agreement with 3SBio,and our ability to successfully capitalize on growth opport